Palivizumab
Palivizumab Brand names, Palivizumab Analogs
Palivizumab Brand Names Mixture
- No information avaliable
Palivizumab Chemical_Formula
No information avaliable
Palivizumab RX_link
http://www.rxlist.com/cgi/generic2/palivizumab.htm
Palivizumab fda sheet
Palivizumab msds (material safety sheet)
Palivizumab Synthesis Reference
sequence listed in Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24.
Palivizumab Molecular Weight
No information avaliable
Palivizumab Melting Point
61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
Palivizumab H2O Solubility
No information avaliable
Palivizumab State
Liquid
Palivizumab LogP
No information avaliable
Palivizumab Dosage Forms
Powder for solution
Palivizumab Indication
For treatment of respiratory diseases casued by respiratory syncytial virus
Palivizumab Pharmacology
Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.
Palivizumab Absorption
No information avaliable
Palivizumab side effects and Toxicity
No information avaliable
Palivizumab Patient Information
No information avaliable
Palivizumab Organisms Affected
No information avaliable
